CFTR and cystic fibrosis: Further, ICM demonstrated that the combination of the CFTR corrector lumacaftor with the potentiator ivacaftor as the first CFTR modulator combination therapy approved for the treatment of CF patients homozygous for the common F508del mutation leads to partial rescue of CFTR activity to levels of ~15–20% of normal CFTR function in healthy controls [45,46].